BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11470774)

  • 1. Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors.
    Warren HS; Campbell AJ; Waldron JC; Lanier LL
    Int Immunol; 2001 Aug; 13(8):1043-52. PubMed ID: 11470774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
    David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
    J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2.
    Vitale M; Carlomagno S; Falco M; Pende D; Romeo E; Rivera P; Della Chiesa M; Mavilio D; Moretta A
    Int Immunol; 2004 Oct; 16(10):1459-66. PubMed ID: 15314042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using carboxyfluorescein diacetate succinimidyl ester to monitor human NK cell division: analysis of the effect of activating and inhibitory class I MHC receptors.
    Warren HS
    Immunol Cell Biol; 1999 Dec; 77(6):544-51. PubMed ID: 10571676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
    Barakonyi A; Rabot M; Marie-Cardine A; Aguerre-Girr M; Polgar B; Schiavon V; Bensussan A; Le Bouteiller P
    J Immunol; 2004 Nov; 173(9):5349-54. PubMed ID: 15494480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies.
    David G; Morvan M; Gagne K; Kerdudou N; Willem C; Devys A; Bonneville M; Folléa G; Bignon JD; Retière C
    Immunology; 2009 Oct; 128(2):172-84. PubMed ID: 19740374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition.
    Winter CC; Gumperz JE; Parham P; Long EO; Wagtmann N
    J Immunol; 1998 Jul; 161(2):571-7. PubMed ID: 9670929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
    Bakker AB; Phillips JH; Figdor CG; Lanier LL
    J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements.
    Vely F; Peyrat M; Couedel C; Morcet J; Halary F; Davodeau F; Romagne F; Scotet E; Saulquin X; Houssaint E; Schleinitz N; Moretta A; Vivier E; Bonneville M
    J Immunol; 2001 Feb; 166(4):2487-94. PubMed ID: 11160309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy.
    Norris S; Doherty DG; Curry M; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
    Cancer Immunol Immunother; 2003 Jan; 52(1):53-8. PubMed ID: 12536240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutting edge: selective expression of inhibitory or activating killer cell Ig-like receptors in circulating CD4+ T lymphocytes.
    Remtoula N; Bensussan A; Marie-Cardine A
    J Immunol; 2008 Mar; 180(5):2767-71. PubMed ID: 18292496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antibody combination to identify KIR2DS2
    Blunt MD; Rettman P; Bastidas-Legarda LY; Fulton R; Capizzuto V; Naiyer MM; Traherne JA; Khakoo SI
    HLA; 2019 Jan; 93(1):32-35. PubMed ID: 30381896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Killer cell Ig-like receptor and leukocyte Ig-like receptor transgenic mice exhibit tissue- and cell-specific transgene expression.
    Belkin D; Torkar M; Chang C; Barten R; Tolaini M; Haude A; Allen R; Wilson MJ; Kioussis D; Trowsdale J
    J Immunol; 2003 Sep; 171(6):3056-63. PubMed ID: 12960331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
    Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction.
    Spaggiari GM; Contini P; Dondero A; Carosio R; Puppo F; Indiveri F; Zocchi MR; Poggi A
    Blood; 2002 Dec; 100(12):4098-107. PubMed ID: 12393468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
    Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
    J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
    Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
    Front Immunol; 2021; 12():640672. PubMed ID: 34017328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies with various reactivity to p58 killer inhibitory receptors.
    Shin JS; Shin EC; Kim J; Choi IH; Park JH; Kim SJ
    Hybridoma; 1999 Dec; 18(6):521-7. PubMed ID: 10626681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.